Improve cognition and motor function
- Trial ID
- NCT05307055
- Official Title
- Theta Burst Subthalamic Nucleus Deep Brain Stimulation for Cognitive and Motor Improvements in Parkinson's Disease
- Goal
- Improve cognition and motor function
- Phase
- NA
- Status
- RECRUITING
- Sponsor
- University of Southern California
- Study Type
- INTERVENTIONAL
- Enrollment
- 40 participants
- Conditions
- Parkinson Disease
- Interventions
- STN DBS - Theta Burst, STN DBS - Gamma
Plain-Language Summary
The goal is to see whether a theta burst pattern of stimulation to the subthalamic nucleus can improve thinking and movement in people with Parkinson's compared with a gamma pattern. The approach uses already-implanted bilateral STN deep brain stimulators and reprograms them to deliver short bursts at theta frequency, which aims to nudge brain rhythms linked to cognition and motor control; this is a device programming change, not a new drug, and meds like levodopa are kept stable so the stimulation’s effect is tested on top of usual therapy. The study is enrolling adults 18 and older who already have bilateral STN DBS, have had stable Parkinson medications for at least three months, can consent and attend follow-ups, and excludes those with a history of seizures, dementia, or major substance abuse.
Locations
- University of Southern California Keck School of Medicine, Los Angeles, California, United States
Frequently Asked Questions
- What is this trial testing?
- This trial is studying STN DBS - Theta Burst. The goal is to see whether a theta burst pattern of stimulation to the subthalamic nucleus can improve thinking and movement in people with Parkinson's compared with a gamma pattern. The approach uses already-implanted bilateral STN deep brain stimulators and reprograms them to deliver short bursts at theta frequency, which aims to nudge brain rhythms linked to cognition and motor control; this is a device programming change, not a new drug, and meds like levodopa are kept stable so the stimulation’s effect is tested on top of usual therapy. The study is enrolling adults 18 and older who already have bilateral STN DBS, have had stable Parkinson medications for at least three months, can consent and attend follow-ups, and excludes those with a history of seizures, dementia, or major substance abuse.
- Who can participate?
- Participants must be at least 18 Years.
- Where is this trial located?
- This trial is recruiting at 1 location.
- Does it cost anything to join?
- No. There is no cost to participate. Study-related care and treatment are provided at no charge.
- How long does the trial last?
- This trial is estimated to last approximately 7 years and 8 months.